Q3 EPS Estimates for Exact Sciences Lifted by William Blair

Key Points

• William Blair has raised its Q3 2025 earnings per share estimate for Exact Sciences from $0.11 to $0.13, while also providing projections for Q1-Q3 2026 and full-year 2026 earnings.
• Despite improving estimates, several analysts have adjusted their target prices downward, with Royal Bank Of Canada lowering theirs to $46 and Barclays to $55, reflecting a cautionary outlook on the stock.
• Exact Sciences reported a strong Q2 with an EPS of $0.22, exceeding expectations and showing a 16% increase in quarterly revenue year-over-year.

Exact Sciences Corporation (NASDAQ:EXAS - Free Report) - William Blair boosted their Q3 2025 EPS estimates for shares of Exact Sciences in a research report issued on Wednesday, September 10th. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings per share of $0.13 for the quarter, up from their previous estimate of $0.11. The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. William Blair also issued estimates for Exact Sciences' Q1 2026 earnings at $0.14 EPS, Q2 2026 earnings at $0.30 EPS, Q3 2026 earnings at $0.33 EPS and FY2026 earnings at $1.13 EPS.

Several other equities research analysts have also issued reports on EXAS. Craig Hallum raised their target price on shares of Exact Sciences from $65.00 to $85.00 and gave the stock a "buy" rating in a report on Thursday. Wall Street Zen upgraded shares of Exact Sciences from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Zacks Research lowered shares of Exact Sciences from a "strong-buy" rating to a "hold" rating in a report on Thursday, September 4th. Evercore ISI decreased their price objective on shares of Exact Sciences from $68.00 to $64.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Finally, Piper Sandler decreased their price objective on shares of Exact Sciences from $70.00 to $60.00 and set an "overweight" rating for the company in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $68.05.

Exact Sciences Trading Down 3.7%

Shares of Exact Sciences stock traded down $2.06 during trading on Friday, hitting $53.94. The stock had a trading volume of 2,321,082 shares, compared to its average volume of 2,759,898. The firm's fifty day simple moving average is $48.86 and its 200-day simple moving average is $49.30. The stock has a market cap of $10.21 billion, a PE ratio of -9.93, a PEG ratio of 4.98 and a beta of 1.05. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.89 and a quick ratio of 2.56. Exact Sciences has a 12 month low of $38.81 and a 12 month high of $72.83.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.24. The firm had revenue of $811.09 million during the quarter, compared to analyst estimates of $774.43 million. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The business's revenue was up 16.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.09) EPS.

Institutional Investors Weigh In On Exact Sciences

Several large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its holdings in shares of Exact Sciences by 463.0% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 1,216 shares of the medical research company's stock valued at $65,000 after purchasing an additional 1,000 shares in the last quarter. Forefront Wealth Partners LLC purchased a new position in shares of Exact Sciences in the 2nd quarter worth approximately $208,000. Marex Group plc purchased a new position in shares of Exact Sciences in the 2nd quarter worth approximately $341,000. Geneos Wealth Management Inc. grew its position in shares of Exact Sciences by 68.6% in the 2nd quarter. Geneos Wealth Management Inc. now owns 1,915 shares of the medical research company's stock worth $102,000 after buying an additional 779 shares during the last quarter. Finally, Corient Private Wealth LLC grew its position in shares of Exact Sciences by 28.9% in the 2nd quarter. Corient Private Wealth LLC now owns 16,737 shares of the medical research company's stock worth $889,000 after buying an additional 3,748 shares during the last quarter. Institutional investors own 88.82% of the company's stock.

Insider Activity at Exact Sciences

In other news, Director James Edward Doyle sold 1,485 shares of the business's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $42.02, for a total value of $62,399.70. Following the completion of the sale, the director owned 59,962 shares in the company, valued at approximately $2,519,603.24. The trade was a 2.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.